Antimicrobial Agents and Chemotherapy, July 2006, p. 2553-2556, Vol. 50, No. 7
0066-4804/06/$08.00+0 doi:10.1128/AAC.00092-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients
Marc Wirden,1,4*
Bénédicte Roquebert,4
Anne Derache,4
Anne Simon,2
Claudine Duvivier,3
Jade Ghosn,3
Stephanie Dominguez,3
Véronique Boutonnet,1
Zaina Ait-Arkoub,1
Christine Katlama,3
Vincent Calvez,1,4 and
Anne-Genevieve Marcelin1,4
Departments of Virology,1
Internal Medicine,2
Infectious Diseases, Pitié-Salpêtrière Hospital, Paris, France,3
Université Pierre et Marie Curie-Paris 6, EA 2387, Paris, F-75013 France4
Received 23 January 2006/
Returned for modification 24 March 2006/
Accepted 25 April 2006
We analyzed 3,475 human immunodeficiency virus sequences and 241 therapeutic histories. The L74I mutation was carried by 7% of viruses. L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz.
* Corresponding author. Mailing address: Pitié-Salpêtrière Hospital, Department of Virology, CERVI, 83, blvd de l'hôpital, 75013 Paris, France. Phone: 33142177401. Fax: 33142177411. E-mail: marc.wirden{at}psl.aphp.fr.
Antimicrobial Agents and Chemotherapy, July 2006, p. 2553-2556, Vol. 50, No. 7
0066-4804/06/$08.00+0 doi:10.1128/AAC.00092-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Copyright © 2006 by the American Society for Microbiology. All rights reserved.